{
    "clinical_study": {
        "@rank": "62250", 
        "acronym": "HER2", 
        "arm_group": {
            "arm_group_label": "gastric adenocarcinoma"
        }, 
        "brief_summary": {
            "textblock": "The objective of this study is to investigate the proportion of HER2 overexpression in\n      gastric cancer patients group, to evaluate the relation of HER2 overexpression with\n      prognosis, and to analyze the proportion of herceptin applied to patients in clinical field.\n      Furthermore, the investigators are going to reevaluate the clinical benefit of Herceptin for\n      survival prolongation compared to chemotherapy only."
        }, 
        "brief_title": "Investigation of the Proportion of Human Epidermal Growth Factor Receptor 2 Protein Overexpression of Gastric Adenocarcinoma and Prognostic Effect of HER2, and Analysis of Practice Pattern of Herceptin Use in Stage IV Gastric Cancer", 
        "condition": "Stomach Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Stomach Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically confirmed gastric adenocarcinoma\n\n          2. Patients were diagnosed during 2006-2013\n\n          3. HER2 expression status was evaluated in primary gastric cancer or metastatic lesion.\n\n        Exclusion Criteria:\n\n          -  Patients with second primary cancer within 5 years"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "gastric cancer patients in Gangnam Severance Hospital"
            }
        }, 
        "enrollment": {
            "#text": "860", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02136836", 
            "org_study_id": "GSCH-STO13-01", 
            "secondary_id": "Roche"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Genes, erbB-2", 
            "Prognosis"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Gangnam Severance Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "other_outcome": {
            "measure": "The practice pattern of Herceptin use in stage IV gastric cancer", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "overall_official": {
            "affiliation": "Gangnam Severance Hospital, Yonsei University", 
            "last_name": "Jae Yong Cho, M.D.,Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The proportion of HER2 overexpression in gastric cancer patients", 
            "safety_issue": "No", 
            "time_frame": "8 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02136836"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Yonsei University", 
            "investigator_full_name": "Jae Yong Cho", 
            "investigator_title": "Chief of division of medical oncology, Gangnam Severance Hospital", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Gastric cancer specific survival according to HER2 expression in each stage", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "source": "Yonsei University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yonsei University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}